5-Lipoxygenase expression in benign and malignant canine prostate tissues

Veterinary and Comparative Oncology

Volumn 9, Issue 2, 2011, Pages 149-157

  Goodman, L A ^a   Jarrett, C L ^a   Krunkosky, T M ^a   Budsberg, S C ^a   Northrup, N C ^a   Saba, C F ^a   Leroy, B E ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Carcinoma; Dog; Hyperplasia; Immunohistochemistry; Leukotriene; Prostatitis

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; COMPARATIVE STUDY; DOG; DOG DISEASE; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; WESTERN BLOTTING;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BLOTTING, WESTERN; DOG DISEASES; DOGS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

CANIS FAMILIARIS;

EID: 79955982549     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00245.x     Document Type: Article

References (35)

1. Rainsford KD, Ying C and Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. The Journal of Pharmacy and Pharmacology 1996; 48: 46-52.
2. Fogh K, Herlin T and Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. The Journal of Allergy and Clinical Immunology 1989; 83(number 2, part 1): 450-455.
3. Taylor GW, Taylor I, Black P, Maltby NH, Turner N, Fuller RW and Dollery CT. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1: 584-588.
4. Kim DC, Hsu FI, Barrett NA, Friend DS, Grenningloh R, Ho IC, Al-Garawi A, Lora JM, Lam BK, Austen KF and Kanaoka Y. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. Journal of Immunology 2006; 176: 4440-4448.
5. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B and Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 1238-1243.
6. Manev H, Uz T, Sugaya K and Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. The FASEB Journal 2000; 14: 1464-1469.
7. De Caterina R and Zampolli A. From asthma to atherosclerosis - 5-lipoxygenase, leukotrienes, and inflammation. The New England Journal of Medicine 2004; 350: 4-7.
8. Wang D and Dubois RN. Eicosanoids and cancer. Nature Reviews Cancer 10: 181-193.
9. Soumaoro LT, Iida S, Uetake H, Ishiguro M, Takagi Y, Higuchi T, Yasuno M, Enomoto M and Sugihara K. Expression of 5-lipoxygenase in human colorectal cancer. World Journal of Gastroenterology 2006; 12: 6355-6360.
10. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Strouch M, Rao SM, Witt RC, Ternet CA, Talamonti MS, Bell RH and Adrian TA. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clinical Cancer Research 2008; 14: 6525-6530.
11. Jiang WG, Douglas-Jones A and Mansel RE. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2003; 69: 275-281.
12. Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H, Buchler MW, Pour PM and Adrian TE. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. American Journal of Pathology 2002; 161: 421-428.
13. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H and Nakatani T. Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. The Journal of Urology 2003; 170: 1994-1999.
14. Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA and Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis 2005; 26: 785-791.
15. Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS and Chen X. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clinical Cancer Research 2005; 11: 2089-2096.
16. Faronato M, Muzzonigro G, Milanese G, Menna C, Bonfigli AR, Catalano A and Procopio A. Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histology and Histopathology 2007; 22: 1109-1118.
17. Nathoo N, Prayson RA, Bondar J, Vargo L, Arrigain S, Mascha EJ, Suh JH, Barnett GH and Golubic M. Increased expression of 5-lipoxygenase in high-grade astrocytomas. Neurosurgery 2006; 58: 347-354; discussion 347-354.
18. Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, Kawahito Y, Sano H and Nakatani T. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. International Journal of Oncology 2004; 24: 821-827.
19. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG and Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001; 91: 737-743.
20. Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, Takemoto Y, Nakatani T and Yoshimura R. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncology Reports 2007; 18: 99-104.
21. Larre S, Tran N, Fan C, Hamadeh H, Champigneulles J, Azzouzi R, Cussenot O, Mangin P and Olivier JL. PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins & Other Lipid Mediators 2008; 87: 14-19.
22. Tong WG, Ding XZ and Adrian TE. The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells. Biochemical and Biophysical Research Communications 2002; 296: 942-948.
23. Romano M, Catalano A, Nutini M, D'Urbano E, Crescenzi C, Claria J, Libner R, Davi G and Procopio A. 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. The FASEB Journal 2001; 15: 2326-2336.
24. Ghosh J and Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 13182-13187.
25. Narayanan NK, Nargi D, Attur M, Abramson SB and Narayanan BA. Anticancer effects of licofelone (ML-3000) in prostate cancer cells. Anticancer Research 2007; 27: 2393-2402.
26. Giannoni E, Fiaschi T, Ramponi G and Chiarugi P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 2009; 28: 2074-2086.
27. Lai CL, van den Ham R, van Leenders G, van der Lugt J, Mol JA and Teske E. Histopathological and immunohistochemical characterization of canine prostate cancer. The Prostate 2008; 68: 477-488.
28. Leroy BE and Northrup N. Prostate cancer in dogs: comparative and clinical aspects. Veterinary Journal 2009; 180: 149-162.
29. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC and Waters DJ. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. The Prostate 2000; 45: 173-183.
30. Tremblay C, Dore M, Bochsler PN and Sirois J. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. Journal of the National Cancer Institute 1999; 91: 1398-1403.
31. Dore M, Lanthier I and Sirois J. Cyclooxygenase-2 expression in canine mammary tumors. Veterinary Pathology 2003; 40: 207-212.
32. L'Eplattenier HF, Lai CL, van den Ham R, Mol J, van Sluijs F and Teske E. Regulation of COX-2 expression in canine prostate carcinoma: increased COX-2 expression is not related to inflammation. Journal of Veterinary Internal Medicine 2007; 21: 776-782.
33. Chu J and Pratico D. The 5-lipoxygenase as a common pathway for pathological brain and vascular aging. Cardiovascular Psychiatry and Neurology 2009; 2009: 174657.
34. Luo M, Jones SM, Peters-Golden M and Brock TG. Nuclear localization of 5-lipoxygenase as a determinant of leukotriene B4 synthetic capacity. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 12165-12170.
35. Brock TG, McNish RW and Peters-Golden M. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages. The Journal of Biological Chemistry 1995; 270: 21652-21658.